Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (197)	1/30/2001 8:53:21 AM
From: XenaLives	Respond to of 539

Anybody feeling psychic? ________________________________________________________ ADVISORY/IBM to Announce New Proteomics Alliance Business Wire - January 30, 2001 08:16 --(BW HealthWire)-- What: IBM Life Sciences to announce strategic alliance with leading proteomics company. Host: Dr. Caroline Kovac, Vice President of IBM Life Sciences When: Tuesday, January 30, 2001 1 PM - conference call Toll free - 877/552-5575 Please call-in 15 minutes prior (12:45 PM) Royal York Hotel Boardroom on Main Mezzanine Level 100 Front Street West Toronto 416/368-2511 Please contact Leslie Allison Plant of IBM Canada (905/316-6275) or Theo Chisholm of IBM Life Sciences (914/766-1180) for additional information or to schedule interviews following the conference. CONTACT: IBM Canada Leslie Allison Plant, 905/316-6275 or IBM Life Sciences Theo Chisholm, 914/766-1180

To: nigel bates who wrote (197)	1/30/2001 8:54:03 AM
From: nigel bates	Respond to of 539

TORONTO, Jan 30 (Reuters) - The life sciences division of IBM Corp. has said it will forge a strategic alliance with a Canadian company on Tuesday, and analysts said on Monday the link is likely to be with a division of Toronto-based MDS Inc. (Toronto:MDS.TO - news) (NYSE:MDZ - news). International Business Machines Corp. (NYSE:IBM - news) has been striking alliances with companies involved in proteomics -- or the science of analyzing proteins to determine their role in disease -- and currently hosts the Worldwide Genome Database at the Hospital for Sick Children in Toronto. ``IBM will probably do something with MDS. There are no other proteomics companies in Toronto except a small one called Integrative Proteomics,'' said a prominent Canadian biotech analyst. MDS has the infrastructure, laboratories, people and money, but what is missing is the technology to analyze a colossal amount of data, said the analyst. IBM said in September that it had inked an agreement with Incyte Genomics Inc. (NasdaqNM:INCY - news) that will give Incyte access to IBM's DiscoveryLink data management software to analyze complex biological systems. The announcement followed on a $100 million, three-year commitment by IBM to invest in the development of technology, and partnerships to interpret the genetic code. Analysts in Toronto expect a similar alliance with MDS Proteomics in advance of a postponed initial public offering that is expected to peg the market valuation of MDS Proteomics at C$500 million to C$750 million ($333 million to $500 million). ``In Canada the only company that it could be is MDS Proteomics and their model is to build themselves into a technology platform company, so this makes sense,'' said another biotechnology analyst based in Toronto. Shares of MDS were up 10 Canadian cents to C$24.85 in mid-afternoon trading on the Toronto Stock Exchange. On the New York Stock Exchange the shares were off 22 cents at $16.40. IBM stock was up $1.01 at $115.20 in New York.